department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Polivy · pharmadog

pharmadog
drugs
Polivy

drug

patient view →

polatuzumab vedotin

Marketedupdated 2mo ago

by Genentech Inc

Approved

community read0 votes

indications

investigational

DLBCL

all catalysts(4)

approval · 4

POLIVY (POLATUZUMAB VEDOTIN-PIIQ) — FDA approval

polatuzumab vedotin

POLIVY (POLATUZUMAB VEDOTIN-PIIQ) — FDA approval

polatuzumab vedotin

POLIVY (POLATUZUMAB VEDOTIN-PIIQ) — FDA approval

polatuzumab vedotin

POLIVY (POLATUZUMAB VEDOTIN-PIIQ) — FDA approval

polatuzumab vedotin

News(0)

no news has mentioned this drug yet

brand

Polivy

generic

polatuzumab vedotin-piiq

indication

Diffuse Large B-Cell Lymphoma

phase

marketed

Data sources

openFDA · ClinicalTrials.gov

last refreshed 50m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

🐶 often sniffed alongside

top 2

drugPOLIVY16 co-mentions · 4 sources
tagApproval16 co-mentions · 4 sources

Trials studying polatuzumab vedotin

phase2An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphomaactive not recruitingn=211
—A Study to Evaluate the Effectiveness and Safety of Polatuzumab in Real World Clinical Practice Among Adult Chinese Participants With Diffuse Large B-Cell Lymphomarecruitingn=1,000
phase1Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphomarecruitingn=224
phase2A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)recruitingn=594
phase3A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphomaactive not recruitingn=208
phase2Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphomaterminatedn=5
phase2A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphomarecruitingn=496
phase2Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOPactive not recruitingn=125

more trials →